Related Experiment Video
Updated: Jun 17, 2026
09:40
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Toward Optimized Platinum Therapy: A Risk Prediction Model for Toxicity Based on Platinum Accumulation and Its Impact
Xiaoting Huang1, Chen Chen1, Jieting Zheng2
1Pharmacy Intravenous Admixture Service, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Drug Design, Development and Therapy
|June 16, 2026
Summary
High platinum levels in cancer patients significantly increase hospital stay and toxicity risk. A predictive model identifies a threshold of 534.40 μg/L for platinum concentration, aiding personalized chemotherapy.
Area of Science:
- Oncology
- Pharmacokinetics
- Clinical Pharmacology
Background:
- Platinum-based chemotherapy is crucial for treating cancers but faces challenges with cumulative toxicity.
- Understanding platinum accumulation is key to managing long-term efficacy and patient outcomes.
Purpose of the Study:
- To investigate the association between serum platinum concentration and length of hospital stay (LOS).
- To develop a predictive tool for optimizing individualized platinum-based chemotherapy and managing toxicity.
Main Methods:
- A cohort of 300 cancer patients receiving platinum-based chemotherapy was analyzed.
- Serum platinum levels were measured, and LOS and adverse events were recorded.
- A classification and regression tree (CART) model was used for risk prediction.
Main Results:
- Elevated serum platinum concentration (> 534.40 μg/L) significantly prolonged LOS, mediated by reduced red blood cell count (32.3%).
- The CART model identified serum platinum concentration, age, serum creatinine, and specific platinum agents as key predictors of adverse reactions (AUC 0.782, accuracy 75.7%).
Conclusions:
- A serum platinum concentration > 534.40 μg/L is a clinically significant threshold for identifying high-risk patients.
- The developed decision-tree model provides a practical framework for early risk identification and treatment optimization in clinical practice.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...